AVITA Medical Boosts Outlook, Raises Price Target to $3.50

AVITA Medical (NASDAQ: RCEL) recently achieved a key milestone by refinancing its debt, easing short-term cash flow concerns. This move, along with a positive shift from losses to profits, led Lake Street to raise its price target to $3.50 while maintaining a hold rating. Additionally, new clinical data on their integrated wound treatment technologies bolster the company’s growth prospects through 2026. These developments indicate a structural improvement in AVITA's financial and operational position, likely stabilizing its stock on NASDAQ.